The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging
NCT ID: NCT05307627
Last Updated: 2024-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2022-03-14
2023-12-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
NCT02052908
RN624 In Adult Patients With Chronic Low Back Pain
NCT00584870
Changes in mRNA Expression Following Exposure to Naproxen
NCT01090596
Naproxen Pharmacogenetic Study (Project 1, Aim 2)
NCT04449471
Actual Use Trial of Naproxen Sodium
NCT01427803
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Long-term (>5 years) LDN users
Participants who have been using LDN for over 5 years
low-dose naltrexone
LDN doses \<20 mg/day
intermediate-term (1-5 years) LDN users
Participants who have been using LDN for at least 1 year, but shorter than 5 years.
low-dose naltrexone
LDN doses \<20 mg/day
short-term (<12 months) LDN users
Participants who have been using LDN for less than a year. This group will serve as the control group.
low-dose naltrexone
LDN doses \<20 mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
low-dose naltrexone
LDN doses \<20 mg/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Any sex
* Any ethnicity
* Taking LDN
* Willing to complete health questionnaires
* Technologically competent to complete web forms
* Subgroup: willing to undergo blood testing
Exclusion Criteria
* Terminal cancer patients (defined as stage IV and/or with a life expectancy of 12 months or less)
18 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AgelessRx
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sajad Zalzala, MD
Role: PRINCIPAL_INVESTIGATOR
AgelessRx
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AgelessRx
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALRx002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.